1 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Renaissance Pharma Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients hu1418K322A + Temozolomide + Irinotecan - High-Risk Neuroblastoma | Phase 2 / Phase 3 | Recruiting | Renaissance Pharma Ltd. | 144 | 2026-03-30 | 2026-10-26 |
Irinotecan (1) · Temozolomide (1)
Canada (1) · Denmark (1) · France (1) · Germany (1) · Spain (1) · United Kingdom (1) · United States (1)
2025 (1)